Listed Adelaide biopharmaceutical company GroPep Limited (ASX:GRO) has been notified by the European Patent Office that its patent for improved products and manufacturing processes for Whey Growth Factor Extract technology will be granted in major European countries.
Now granted in the USA, Europe, Australia and New Zealand, the patent is one of three patent families protecting the oral mucositis product (PV701) for which GroPep has previously announced positive clinical trial results.
GroPep's Vice President of Commercial Operations, Mr Gregory Moss-Smith, said "The fact that the patent both attracted and survived intense opposition proceedings is an indication of the strength of the patent and its commercial merit."
The Canadian Patent Office has also just granted GroPep a related patent on the Whey Growth Factor technology.
GroPep has licensed these patents to Dutch multi-national DMV Campina and Adelaide-based TGR Biosciences Pty Ltd, to exploit areas outside GroPep's pharmaceutical interests.
GroPep, based at Thebarton, South Australia, listed on the Australian Stock Exchange in August 2000. It specialises in the development, manufacture and commercialisation of biopharmaceuticals and also biologically active proteins for cell culture and biomedical research.
Mr Tony Mitchell
Chief Financial Officer/Investor Relations
Ph: (08) 8354 7700